AAVXF — Abivax S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1956827 ·
France
Last close
$126.00
Market Cap
$10.04B
52W High
$126.00
52W Low
$115.65
ADV30
3
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -56,229,000 | -48,468,000 | 547,142,000 | 477,423,000 | 117,548,000 |
| Dec 2025 | 0 | — | -71,648,000 | -81,960,000 | 584,341,000 | 516,685,000 | 129,136,000 |
| Sep 2025 | 0 | — | -80,712,000 | -153,358,000 | 652,052,000 | 589,703,000 | 140,814,000 |
| Jun 2025 | 0 | — | -46,496,000 | -48,414,000 | 119,641,000 | 60,946,000 | 167,921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,130,000
Investing CF
$-8,193,000
Financing CF
$547,307,000
CapEx
$-243,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-4.56
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-738,482,000
Inventory
—
Receivables
$10,495,000
ST Investments
$13,698,000
EBIT TTM
$-302,711,000
Pretax Income TTM
$-330,254,000
Interest Exp TTM
$27,543,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -246,056,000 | -336,102,000 | 584,341,000 | 129,136,000 | — | -161,129,000 |
| Dec 2024 | 0 | -172,984,000 | -176,242,000 | 205,228,000 | 164,644,000 | — | -154,072,000 |
| Dec 2023 | 0 | -127,377,000 | -147,740,000 | 327,062,000 | 131,052,000 | — | -97,130,000 |
| Dec 2022 | 0 | -51,205,000 | -60,740,000 | 75,544,000 | 68,355,000 | — | -53,936,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVX | Abivax S.A. | $10.07B | $126.41 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.22B | $52.88 | — |
| PRAX | Praxis Precision Medicines, Inc. | $9.77B | $350.60 | — |
| CYTK | CYTOKINETICS INC | $10.36B | $76.29 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $11.08B | $78.68 | — |
News headlines (Yahoo Finance, 1h cache)
ABIVAX Société Anonyme (ENXTPA:ABVX) Is Up 6.9% After Long-Term Obefazimod Data And Q1 Results - Has The Bull Case Changed?
2026-05-24 07:11 · Yahoo
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients
2026-05-22 20:05 · Yahoo
2 Stocks That Could Realistically Double by 2030
2026-05-22 07:35 · Yahoo
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
2026-05-19 17:37 · Yahoo
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
2026-05-19 17:26 · Yahoo
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
2026-05-18 18:43 · Yahoo
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
2026-05-18 18:25 · Yahoo
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
2026-05-18 18:10 · Yahoo
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
2026-05-18 17:44 · Yahoo
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
2026-05-18 17:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.